Publications by authors named "Robert J Fram"

12 Publications

  • Page 1 of 1

Economic burden of elderly patients with acute myeloid leukemia treated in routine clinical care in the United States.

Leuk Res 2018 08 18;71:27-33. Epub 2018 Jun 18.

Winship Cancer Institute of Emory University, 1365-C Clifton Road NE, Atlanta, GA, 30322, USA. Electronic address:

View Article and Find Full Text PDF
August 2018

Transfusion-free interval is associated with improved survival in patients with higher-risk myelodysplastic syndromes engaged in routine care.

Leuk Lymphoma 2019 01 22;60(1):49-59. Epub 2018 Jun 22.

a Millennium Pharmaceuticals, Inc, (a wholly owned subsidiary of Takeda Pharmaceutical Company Limited) , Cambridge , MA , USA.

View Article and Find Full Text PDF
January 2019

Effectiveness and Safety of Therapeutic Regimens for Elderly Patients With Acute Myeloid Leukemia: A Systematic Literature Review.

Clin Lymphoma Myeloma Leuk 2018 07 10;18(7):e303-e314. Epub 2018 May 10.

Millennium Pharmaceuticals Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA.

View Article and Find Full Text PDF
July 2018

Systematic Literature Review of Treatment Options and Clinical Outcomes for Patients With Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia.

Clin Lymphoma Myeloma Leuk 2018 04 8;18(4):e157-e166. Epub 2018 Feb 8.

Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA.

View Article and Find Full Text PDF
April 2018

Pharmacokinetics and antitumor efficacy of XMT-1001, a novel, polymeric topoisomerase I inhibitor, in mice bearing HT-29 human colon carcinoma xenografts.

Clin Cancer Res 2012 May 5;18(9):2591-602. Epub 2012 Mar 5.

Division of Pharmacotherapy & Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina 27599, USA.

View Article and Find Full Text PDF
May 2012

XMT-1001, a novel polymeric camptothecin pro-drug in clinical development for patients with advanced cancer.

Adv Drug Deliv Rev 2009 Nov 12;61(13):1193-202. Epub 2009 Aug 12.

Mersana Therapeutics, Inc., 840 Memorial Drive, Cambridge, MA 02139, USA.

View Article and Find Full Text PDF
November 2009